Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06606028 · ClinicalTrials.gov registry record

Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma

A clinical trial of Squamous Cell Carcinoma of Head and Neck and Cutaneous Squamous Cell Carcinoma (CSCC), sponsored by University of California, San Francisco.

Recruiting
Registry status
250
Enrollment target
1
Study location

NCT06606028: Recruiting study of Squamous Cell Carcinoma of Head and Neck and Cutaneous Squamous Cell Carcinoma (CSCC), sponsored by University of California, San Francisco.

NCT06606028 is a study of Squamous Cell Carcinoma of Head and Neck and Cutaneous Squamous Cell Carcinoma (CSCC) that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 250 participants, above the 164-participant average among 37 other Squamous Cell Carcinoma of Head and Neck trials with a reported enrollment target (52% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06606028, a study of Squamous Cell Carcinoma of Head and Neck and Cutaneous Squamous Cell Carcinoma (CSCC), is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
250 participants
Enrollment target
1
Study location

Study Summary

This is a single-center, non-interventional, observational study that evaluates the correlation of circulating tumor DNA (ctDNA) testing to cancer relapse for participants with squamous cell carcinomas (HNC) of the head and neck mucosa and skin after curative-intent primary radiation or surgery.

Primary Outcome

Cumulative incidence will be estimated by evaluating the cumulative incidence of positive ctDNA (non-zero) with death as a competing risk.

Interventions

  • PROCEDURE Blood Specimen Collection
  • OTHER Medical Record Review
  • PROCEDURE Tumor Tissue Collection

Study Locations (1)

California

  • University of California, San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2024-10-09
Est. Completion 2029-12-30

What NCT06606028 shows while recruiting

NCT06606028 is an observational study that tracks outcomes without assigning an intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, above the 164-participant average among 37 other Squamous Cell Carcinoma of Head and Neck trials with a reported enrollment target (52% higher).

The record links to 4 conditions, with Squamous Cell Carcinoma of Head and Neck appearing as the primary indexed condition, and to 3 interventions - of which Blood Specimen Collection is the first listed.

NCT06606028 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06606028 about?

NCT06606028 is a clinical study titled "Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma". This is a single-center, non-interventional, observational study that evaluates the correlation of circulating tumor DNA (ctDNA) testing to cancer relapse for participants with squamous cell carcinomas (HNC) of the head and neck mucosa and skin after curative-intent primary radiation or surgery.

What is the current status of trial NCT06606028?

This trial is currently recruiting. The enrollment target is 250 participants. The study started on 2024-10-09. Estimated completion is 2029-12-30.

What conditions does trial NCT06606028 study?

This clinical trial studies the following conditions: Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma (CSCC), Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), Squamous Cell Carcinoma of Skin.

What interventions are being tested in trial NCT06606028?

The interventions under investigation include: Blood Specimen Collection (PROCEDURE), Medical Record Review (OTHER), Tumor Tissue Collection (PROCEDURE).

Who is sponsoring clinical trial NCT06606028?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06606028 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Squamous Cell Carcinoma of Head and Neck

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06606028's enrollment target sits among peer trials

250 7th of 37 higher than 30 of 37 other Squamous Cell Carcinoma of Head and Neck trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Squamous Cell Carcinoma of Head and Neck trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00483249 · 250 participants · NA

    Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm

  • NCT00777712 · 250 participants

    Mechanisms Underlying Impaired Diabetic Wound Healing

  • NCT01451502 · 250 participants · NA

    Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

  • NCT01771718 · 250 participants

    Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06606028, the US trial registry maintained by the National Library of Medicine. NCT06606028 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.